Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Certain leukemia oncogenes switch on genetic programs that govern self-renewal, a unique stem cell characteristic

Researchers have discovered that specific cancer-causing genes associated with leukemias can transform mature white blood cells into leukemic cells that have all the properties of stem cells.

21 Dec 2004

Essential oils have been found to kill the deadly MRSA bacteria

Essential oils usually used in aromatherapy have been found to kill the deadly MRSA bacteria according to research carried out at The University of Manchester.

From The University of Manchester 21 Dec 2004

Gene therapy effective in helping children with severe combined immunodeficiency (SCID)

A UK study in this week’s issue of THE LANCET provides further evidence that gene therapy can be effective in creating a functional immune system for infants with severe combined immunodeficiency (SCID).

20 Dec 2004

FDA accepts Genmab's Investigational New Drug Application for active rheumatoid arthritis treatment

Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).

13 Dec 2004

Zarnestra, a farnesyl transferase inhibitor, can help treat high-risk myelodysplastic syndrome patients

An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).

7 Dec 2004

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.

7 Dec 2004

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

CHU in Poitiers, France, yesterday announced results of a study showing that newly diagnosed patients with a certain form of leukemia who are treated early with imatinib are more likely to achieve complete cytogenetic responses (the elimination of leukemic cells, a major goal of therapy) and have improved long-term outcomes.

6 Dec 2004

New drug can successfully treat patients who have become resistant to Gleevec

A team of prominent researchers led by Charles Sawyers, M.D. and Moshe Talpaz, M.D., presented compelling clinical findings today showing that a new drug, BMS-354825, can successfully treat patients who have become resistant to Gleevec (the frontline therapy for chronic myelogenous leukemia, CML).

5 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Genetic target found for pediatric leukemia

A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

A new treatment for patients with chronic myeloid leukemia

A new treatment for patients with chronic myeloid leukemia (CML) -- a disorder marked by an overproduction of white blood cells -- yields positive results in those who have relapsed on imatinib, the standard treatment for the disease, according to a Phase I study to be presented today at the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Oral targeted therapy shows benefit in treating high-risk myelodysplastic syndrome

4 Dec 2004

Human endogenous retroviruses (HERVs)

Human endogenous retroviruses (HERVs) have been the subject of a great deal of investigation in recent years. It has been established that HERVs cause some genetic diseases and there is strong circumstantial evidence for a link to some types of cancer and autoimmune diseases, but what else do we need to know about these unique organisms?

4 Dec 2004

Fossil record of the human immune system reveals antibodies that block cancer metastasis

A team of researchers at The Scripps Research Institute has reconstructed the "fossil record" of the immune systems of a group of human cancer patients to investigate if they had ever produced antibodies against their disease.

4 Dec 2004

Methylphenidate improves attention, behavior of children surviving acute lymphoblastic leukemia, brain tumors

Children who suffer from behavioral and learning problems after their central nervous systems have been exposed to chemotherapy or radiation appear to benefit from treatment with methylphenidate (MPH), the drug commonly known by the brand name Ritalin®.

4 Dec 2004

Low level exposure to Benzene causes lower blood cell counts

A new study found that white blood cell counts were lowered in workers exposed to less than 1 ppm of the chemical benzene (part benzene per million parts air).

3 Dec 2004

Leukemia News and Research

Further Reading

Certain leukemia oncogenes switch on genetic programs that govern self-renewal, a unique stem cell characteristic

Essential oils have been found to kill the deadly MRSA bacteria

Gene therapy effective in helping children with severe combined immunodeficiency (SCID)

FDA accepts Genmab's Investigational New Drug Application for active rheumatoid arthritis treatment

Zarnestra, a farnesyl transferase inhibitor, can help treat high-risk myelodysplastic syndrome patients

Revlimid clinical data in newly diagnosed multiple myeloma presented

Study shows long-term benefits for chronic myeloid leukemia patients receiving therapy with imatinib

New drug can successfully treat patients who have become resistant to Gleevec

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Researchers step closer to cure for common childhood cancer

Genetic target found for pediatric leukemia

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

A new treatment for patients with chronic myeloid leukemia

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

Single dose phase I data on CG53135 for the prevention of oral mucositis

Oral targeted therapy shows benefit in treating high-risk myelodysplastic syndrome

Human endogenous retroviruses (HERVs)

Fossil record of the human immune system reveals antibodies that block cancer metastasis

Methylphenidate improves attention, behavior of children surviving acute lymphoblastic leukemia, brain tumors

Low level exposure to Benzene causes lower blood cell counts

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News